Effect of postnecrotic and alcoholic hepatic cirrhosis on development of benign prostatic hyperplasia

Çetinkaya, Mesut; Çetinkaya, Hülya; Ulusoy, Ercüment; Baz, Sedat; Memiş, Ali; Yaşa, Hadi; Yanık, Bahar; Öztürk, Bülent; Uzunalımoǧlu, Özden

doi:10.1002/(sici)1097-0045(19980701)36:2<80::aid-pros2>3.0.co;2-i

Cited by 11 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in agreement with previous studies which found that cirrhotic patients have significantly lower PSA levels than men with normal liver function 21–22. Furthermore, liver dysfunction, which has been shown to influence the development of BPH, is associated with smaller prostate size 23. This association between liver function and prostate size may further contribute to lower PSA levels in men with hepatic dysfunction.…”

Section: Discussionsupporting

confidence: 92%

The influence of hepatic function on prostate cancer outcomes after radical prostatectomy

Bañez

Loftis

Freedland

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Prostate growth is dependent on circulating androgens which can be influenced by hepatic function. Liver disease has been suggested to influence prostate cancer (CaP) incidence. However, the effect of hepatic function on CaP outcomes has not been investigated. A total of 1,181 patients who underwent radical prostatectomy (RP) between 1988 and 2008 at four Veterans Affairs hospitals that comprise the Shared Equal Access Regional Cancer Hospital (SEARCH) database and had available liver function test (LFT) data were included in the study. Independent associations of LFTs with unfavorable pathological features and biochemical recurrence were determined using logistic and Cox regression analyses. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) levels were elevated in 8.2% and 4.4% of patients, respectively. After controlling for CaP features, logistic regression revealed a significant association between SGOT levels and pathological Gleason sum ≥7(4+3) cancer (odds ratio=2.12; 95% confidence interval=1.11-4.05; p=0.02). Mild hepatic dysfunction was significantly associated with adverse CaP grade but was not significantly associated with other adverse pathological features or biochemical recurrence in a cohort of men undergoing R. The effect of moderate to severe liver disease on disease outcomes in CaP patients managed non-surgically remains to be investigated.

show abstract

Section: Discussionsupporting

confidence: 92%

The influence of hepatic function on prostate cancer outcomes after radical prostatectomy

Bañez

Loftis

Freedland

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Moreover, the restoration of normal hepatocellular functions by liver transplantation did not modify serum PSA level [24]. Conversely, a slight decrease in PSA was described in relation to a decrease in testosterone and an increase in the estradiol/free testosterone ratio in cirrhotic male patients [25]. Globally, PSA remains a reliable prostate tumor marker in patients with chronic liver diseases.…”

Section: Discussionmentioning

confidence: 95%

Prostate-specific antigen in acute hepatitis and hepatocellular carcinoma

et al. 1999

View full text Add to dashboard Cite

BACKGROUND Prostate‐specific antigen (PSA) is the most important tumor marker in prostate cancer diagnosis and follow‐up. Its catabolism by the liver has not influenced its use as a prostate marker until the recent report of a significant increase in a man and a woman with acute hepatitis. In addition, PSA was detected in liver tumor extracts, which warranted its evaluation in liver cytolysis and hepatocellular carcinoma. In this study, PSA was evaluated in a cohort of both sexes presenting either acute hepatitis or hepatocellular carcinoima. METHODS Forty‐two patients with acute hepatitis (21 male patients, 21 female patients) and 54 patients with hepatocellular carcinoma (31 male patients, 23 female patients) were tested for PSA by equimolar immunoassay (Abbott AxSYM Total PSA, Abbott Diagnostics, Rungis, France) and for relevant liver biological parameters (alpha‐fetoprotein, alanine aminotransferase, aspartate aminotransferase, total bilirubin, and prothrombin rate). RESULTS PSA was undetectable in all the female patients and was consistent with age in the males (PSA median and range in acute hepatitis, 0.36 μg/l (range, 0.05–1.3); in hepatocellular carcinoma, 0.36 μg/l (range, 0.02–3.9)). It did not correlate with alpha‐fetoprotein and aminotransferases. CONCLUSIONS Our results confirm the well‐established reliability of PSA, and show that PSA remains a valid prostate marker in patients with acute hepatitis and hepatocellular carcinoma. Prostate 41:258–262, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

“…Frea et al reported that the prevalence of BPH in patients with cirrhosis was 41% whereas that in controls was 71% [ 18 ]. Mesut et al demonstrated that the mean prostate volume was 17.9 ± 6.8 cm 3 in patients with cirrhosis (n = 60) whereas it was 27.6 ± 8.6 cm 3 in controls (n = 20) [ 19 ]. These results could be partly explained by the fact that the prostatic epithelium responds to androgens, the level of which is reduced in patients with cirrhosis [ 18 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…Mesut et al demonstrated that the mean prostate volume was 17.9 ± 6.8 cm 3 in patients with cirrhosis (n = 60) whereas it was 27.6 ± 8.6 cm 3 in controls (n = 20) [ 19 ]. These results could be partly explained by the fact that the prostatic epithelium responds to androgens, the level of which is reduced in patients with cirrhosis [ 18 19 ]. This was consistent with the finding in our study that the prostate volume in the baseline CT was larger in patients without liver dysfunction (26.9 ± 9.1 cm 3 ) when compared to those with liver dysfunction (22.4 ± 14.7 cm 3 ), although the difference between the two groups was not statistically significant (p = 0.178).…”

Section: Discussionmentioning

confidence: 99%

Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study

Takahashi

Masuoka

Nasu

et al. 2018

Journal of the Belgian Society of Radiology

View full text Add to dashboard Cite

Background:Sorafenib has been used in the treatment of advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Sorafenib-associated organ reduction have been reported on imaging, such as thyroid, pancreas and muscle, but there has been no research on prostate volume reduction (PVR).Methods:We retrospectively analyzed 26 patients (twenty with HCC and six patients with RCC) who underwent sorafenib therapy for 31 to 1225 days (median, 100 days). PVR was estimated by two independent readers using CT volumetry.Results:The sum of all prostate volumes measured by reader 1 was 24.2 ± 13.8 cm3 on the baseline CT and 20.4 ± 10.6 cm3 on the follow-up CT (p < 0.001), and that measured by reader 2 was 22.3 ± 13.9 cm3 on the baseline CT and 19.2 ± 10.6 cm3 on the follow-up CT (p < 0.001). The concordance correlation coefficient for the prostate volume measured by the two readers was 0.95 on the baseline CT scans and 0.94 on the follow-up CT scans. Sorafenib-associated PVR demonstrated slight dependence to the exposure time (r = –0.23). One patient with benign prostatic hyperplasia (BPH) showed PVR (from 80.4 to 61.5 cm3 [reader 1]; 83.4 to 61.6 cm3 [reader 2]) after sorafenib administration. Sorafenib-associated PVR occurred in patients both with and without underlying liver dysfunction with relative prostate volume changes of 86.7 ± 12.0% and 85.0 ± 9.0%, respectively.Conclusion:Our study demonstrated significant PVR with sorafenib treatment in patients regardless of the presence of BPH and underlying liver dysfunction.

show abstract

Effect of postnecrotic and alcoholic hepatic cirrhosis on development of benign prostatic hyperplasia

Cited by 11 publications

References 25 publications

The influence of hepatic function on prostate cancer outcomes after radical prostatectomy

The influence of hepatic function on prostate cancer outcomes after radical prostatectomy

Prostate-specific antigen in acute hepatitis and hepatocellular carcinoma

Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study

Contact Info

Product

Resources

About